GSA Capital Partners’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

GSA Capital Partners’s Portfolio ZYNE Stock Details ZYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-131,036	Closed	-$96K	–	2009
2022 Q3	$96K	Sell	131,036 -1,369	-1%	-$1.55K	0.01%	1368
2022 Q2	$151K	Sell	132,405 -18,509	-12%	-$23.6K	0.02%	1143
2022 Q1	$309K	Sell	150,914 -119,858	-44%	-$285K	0.04%	871
2021 Q4	$780K	Buy	270,772 +236,984	+701%	+$877K	0.1%	327
2021 Q3	$143K	Buy	+33,788	New	+$151K	0.01%	1290
2020 Q1	–	Sell	-22,106	Closed	-$134K	–	1679
2019 Q4	$134K	Buy	+22,106	New	+$151K	0.02%	1318
2018 Q4	–	Sell	-21,700	Closed	-$177K	–	1843
2018 Q3	$177K	Buy	+21,700	New	+$167K	0.01%	1509
2018 Q1	–	Sell	-38,800	Closed	-$486K	–	1883
2017 Q4	$486K	Buy	+38,800	New	+$445K	0.03%	952
2017 Q3	–	Sell	-10,900	Closed	-$185K	–	1937
2017 Q2	$185K	Sell	10,900 -19,900	-65%	-$396K	0.01%	1519
2017 Q1	$619K	Buy	30,800 +17,100	+125%	+$340K	0.03%	965
2016 Q4	$214K	Buy	+13,700	New	+$185K	0.01%	1561

Other funds holding ZYNE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PCM

Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

IEFM

IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return

GSA Capital Partners's ZYNE Position: Q4 2022 in Review

GSA Capital Partners sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q4 2022, closing a stake of 131,036 shares — an estimated $96K sold.

GSA Capital Partners first reported a position in ZYNE in Q4 2016 and held it in 11 quarters. The position peaked at $780K in Q4 2021. 50 funds tracked by Wall St. Rank hold ZYNE as of Q4 2022.

GSA Capital Partners reported no remaining Zynerba Pharmaceuticals, Inc position as of Q4 2022 after selling out during the quarter.
GSA Capital Partners sold 131,036 Zynerba Pharmaceuticals, Inc shares in Q4 2022, an estimated $96K.
GSA Capital Partners first reported a position in Zynerba Pharmaceuticals, Inc in Q4 2016 and held it in 11 quarters.
GSA Capital Partners's Zynerba Pharmaceuticals, Inc position peaked at $780K in Q4 2021.
50 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q4 2022.

Based on GSA Capital Partners's 13F filing for Q4 2022, filed 13 Feb 2023.